ArticleDiscover oncology2025
Characterization of T cell markers in endometrial carcinoma through single-cell RNA sequencing.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial carcinoma is a leading gynecological malignancy worldwide and is frequently associated with poor prognosis in advanced-stage patients. Immunotherapy has emerged as a promising treatment modality in endometrial cancer. T cells are recognized as vital mediators of immunosurveillance and cancer eradication.
methodsIn this study, we leveraged single-cell RNA sequencing data from the GSE173682 dataset to identify T cell marker genes. Additionally, we collected bulk RNA sequencing data and clinical data from 544 endometrial cancer patients to construct a predictive model. We further explored the correlations between this model and immunotherapy response, drug sensitivity, and mutation status.
resultsWe developed an eight-gene prediction signature based on T cell marker genes, which demonstrated high accuracy in predicting the prognosis of endometrial cancer patients. The area under the receiver operating characteristic curve was 0.838 at 5 years. This T cell-related signature was strongly associated with immune-related function scores and showed potential for predicting responses to both immunotherapy and chemotherapy in endometrial cancer patients.
conclusionWe have established a robust prognostic model based on T cell genes. This model may contribute to the development of more precise therapeutic strategies in the management of endometrial cancer, though further validation is needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.